Sign Up
Stories
Arcutis Initiates $150 Million Offering
Share
ADR Surge and Drops in NY
APi Group's Stock Offering Update
Arcus Biosciences Employs Inducement Gra...
ABIO ARCA Revenue Analysis
ARCA Biopharma Revenue Insights
Acquisition Progress Amid Safety Concern
Overview
API
Arcutis Biotherapeutics, Inc. disclosed the pricing of a $150 million public offering for its common stock to advance dermatology programs, focusing on atopic dermatitis and scalp psoriasis. The offering is set to conclude on March 4, 2024.
Ask a question
How could this public offering influence the landscape of dermatological pharmaceutical companies?
How might the $150 million offering impact Arcutis' market position in the dermatology sector?
What potential innovations or advancements could result from the funds allocated to atopic dermatitis and scalp psoriasis treatments?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage